Dr Kenneth Custer, Lilly's executive vice president, said: "The 12mg dose delivered a level of weight loss long associated with bariatric surgery." Professor Ania Jastreboff, lead investigator on the trial at Yale School of Medicine, added: "Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease
Initially, only celebrities and fashion industry A-listers (and people with diabetes) seemed to be able to get their hands on Ozempic, but the shortages only led to a rise in readily available FDA-approved alternatives
In addition, GLP-1 activates stretch receptors in the small intestine, which in turn signal to the hypothalamus to reduce appetite and increase energy expenditure
Yes, provided it's physician-supervised
Agonistas del receptor de GLP-1 (GLP-1 RA): Estos medicamentos imitan la accin de GLP-1 natural pero estn modificados para resistir la degradacin por DPP-4, prolongando su efecto
